Drug Interactions between eptifibatide and heparin
This report displays the potential drug interactions for the following 2 drugs:
- eptifibatide
- heparin
Interactions between your drugs
heparin eptifibatide
Applies to: heparin and eptifibatide
MONITOR CLOSELY: Although glycoprotein IIb/IIIa inhibitors are routinely given with heparin, be cognizant of the increased risk of bleeding due to additive pharmacologic effects. Data have shown increased incidences of major bleeding complications, including hemorrhagic stroke, retroperitoneal bleeding, spontaneous gastrointestinal (GI) and genitourinary (GU) bleeding among patients receiving both agents compared with the risk associated with the use of either agent alone. Arterial puncture sites may be most problematic. Fatal bleeding episodes have been reported. Some clinical trials have reported higher rates of hemorrhagic stroke in patients receiving abciximab plus standard heparin doses than in patients receiving low-dose, weight-adjusted heparin doses.
MANAGEMENT: Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. Glycoprotein inhibitor/heparin therapy should be discontinued immediately if serious or uncontrollable bleeding occurs or if thrombocytopenia is confirmed. Low-dose, weight-adjusted heparin is recommended in patients who are receiving abciximab and undergoing percutaneous coronary intervention. Heparin should be discontinued for 3 to 4 hours before removing the sheath.
References
- "Product Information. ReoPro (abciximab)." Lilly, Eli and Company PROD (2001):
- "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc PROD (2001):
- "Product Information. Integrilin (eptifibatide)." Schering Corporation PROD (2001):
- Blankenship JC "Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors." Am Heart J 138 (1999): s287-96
- Juran NB "Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy." Am Heart J 138 (1999): s297-306
- Caillard S, Leray C, Kunz K, Gachet C, Offner M, Wiesel ML, Hannedouchte T, Cazenave JP, Moulin B "Effects of cerivastatin on lipid profiles, lipid peroxidation and platelet and endothelial activation in renal transplant recipients." Transplant Proc 32 (2000): 2787-8
- Adderhuis KM, Deckers JW, Lincoff AM, et al. "Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention." JAMA 286 (2001): 78-82
- Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest 119(1 Suppl) (2001): 1S-2S
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.